Literature DB >> 25710201

Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer.

Nima Wesseltoft-Rao1, Marianne J Hjermstad, Tone Ikdahl, Olav Dajani, Stine M Ulven, Per Ole Iversen, Asta Bye.   

Abstract

There is no universally accepted definition of cancer cachexia. Two classifications have been proposed; the 3-factor classification requiring ≥ 2 of 3 factors; weight loss ≥ 10%, food intake ≤ 1500 kcal/day, and C-reactive protein ≥ 10 mg/l, and the consensus classification requiring weight loss >5% the past 6 mo, or body mass index <20 kg/m(2) or sarcopenia, both with ongoing weight loss >2%. Precachexia is the initial stage of the cachexia trajectory, identified by weight loss ≤ 5%, anorexia and metabolic change. We examined the consistency between the 2 classifications, and their association with survival in a palliative cohort of 45 (25 men, median age of 72 yr, range 35-89) unresected pancreatic cancer patients. Computed tomography images were used to determine sarcopenia. Height/weight/C-reactive protein and survival were extracted from medical records. Food intake was self-reported. The agreement for cachexia and noncachexia was 78% across classifications. Survival was poorer in cachexia compared to noncachexia (3-factor classification, P = 0.0052; consensus classification, P = 0.056; when precachexia was included in the consensus classification, P = 0.027). Both classifications showed a trend toward lower median survival (P < 0.05) with the presence of cachexia. In conclusion, the two classifications showed good overall agreement in defining cachectic pancreatic cancer patients, and cachexia was associated with poorer survival according to both.

Entities:  

Mesh:

Year:  2015        PMID: 25710201     DOI: 10.1080/01635581.2015.1004728

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  10 in total

1.  TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia.

Authors:  Kevin G Burfeind; Xinxia Zhu; Peter R Levasseur; Katherine A Michaelis; Mason A Norgard; Daniel L Marks
Journal:  Brain Behav Immun       Date:  2018-05-28       Impact factor: 7.217

Review 2.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

3.  Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer.

Authors:  Asta Bye; Nima Wesseltoft-Rao; Per Ole Iversen; Grete Skjegstad; Kirsten B Holven; Stine Ulven; Marianne J Hjermstad
Journal:  Med Oncol       Date:  2016-04-27       Impact factor: 3.064

Review 4.  Symptoms During Outpatient Cancer Treatment and Options for Their Management

Authors:  Mitra Tewes; Freerk Baumann; Martin Teufel; Christoph Ostgathe
Journal:  Dtsch Arztebl Int       Date:  2021-04-30       Impact factor: 5.594

5.  The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts.

Authors:  H Lee Sweeney; Stefano Masiero; Ugo Carraro
Journal:  Eur J Transl Myol       Date:  2022-03-10

6.  The influence of different muscle mass measurements on the diagnosis of cancer cachexia.

Authors:  Susanne Blauwhoff-Buskermolen; Jacqueline A E Langius; Annemarie Becker; Henk M W Verheul; Marian A E de van der Schueren
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-04-26       Impact factor: 12.910

7.  Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.

Authors:  Louise E Daly; Éadaoin B Ní Bhuachalla; Derek G Power; Samantha J Cushen; Karl James; Aoife M Ryan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-01-09       Impact factor: 12.910

8.  Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients.

Authors:  Anne Gingrich; Dorothee Volkert; Eva Kiesswetter; Marta Thomanek; Svenja Bach; Cornel C Sieber; Yurdagül Zopf
Journal:  BMC Geriatr       Date:  2019-04-27       Impact factor: 3.921

9.  The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer.

Authors:  Henrique A Parsons; Vickie E Baracos; David S Hong; James Abbruzzese; Eduardo Bruera; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-04-12

10.  Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas.

Authors:  Cynthia Stretch; Jean-Michel Aubin; Beata Mickiewicz; Derek Leugner; Tariq Al-Manasra; Elizabeth Tobola; Santiago Salazar; Francis R Sutherland; Chad G Ball; Elijah Dixon; Hans J Vogel; Sambasivario Damaraju; Vickie E Baracos; Oliver F Bathe
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.